Fidelity European Trust outperforms as financial, health care and cosmetic stocks rise

Fidelity

Fidelity European Trust PLC (LON:FEV) monthly factsheet for the period ended 31 March 2023.

Portfolio Manager Commentary

Continental European equities delivered a small positive return over March, despite significant volatility due to the collapse of Silicon Valley and Signature Banks in the US and subsequent failure of Credit Suisse in Europe, which led to fears of wider contagion in the banking sector. Despite the market volatility, the European Central Bank (ECB) raised rates by 0.5% as expected in March. The central bank reassured markets that it is “fully equipped” to provide additional support to the banking system to preserve financial stability. ECB President Christine Lagarde continued to signal that further rate hikes would be based on data releases and observed that “inflation is projected to remain too high for too long”. That
said, headline inflation in the eurozone fell to 6.9% in March from 8.5% in February.

During the month, the Trust recorded positive returns and outperformed the index. The outperformance was driven by the overweight in consumer discretionary and technology, and strong stock picking in financials. At a stock level, cosmetics major L’Oreal was the biggest contributor as shares advanced on broker upgrades. Health care companies Novo Nordisk and Sanofi were also among the strong performers.

On a rolling 12-month basis, the Trust recorded NAV and share price returns of 12.6% and 14.1% respectively, compared to 8.7% for the index.

Fidelity European Trust PLC (LON:FEV) is a European investment trust. It  aims to be the cornerstone long-term investment of choice for those seeking European exposure across market cycles.

Share on:
Find more news, interviews, share price & company profile here for:

Are European equities set for a revival?

Marcel Stötzel, Co-Portfolio Manager of Fidelity European Trust, remains positive on Europe’s investment outlook, citing structural reforms, rising defence spending and potential economic integration as key drivers.

Fidelity European Trust continued rise as shares advanced in ASML and AIB

Fidelity European Trust has published its September 2025 factsheet, noting European equities finished the quarter higher despite mixed sector performance.

Investing in Europe: Why investors should remain positive

Co-Portfolio Manager of the Fidelity European Trust PLC (LON:FEV), outlines why he believes quality businesses backed by strong balance sheets and dividend growth potential remain well placed to deliver strong relative returns over the long-term.

Fidelity European Trust rises in August, reporting 16.4% returns in 2025

Fidelity European Trust highlighted strong contributions in August 2025 from KBC Groupe, which upgraded full year guidance, and Novo Nordisk, which advanced on positive trial results and regulatory approval for Wegovy.

Fidelity European Trust Factsheet – July volatility, Legrand and Bankinter gains

Continental European equities were volatile in July, with the Trust underperforming the index due to weak stock selection in financials and healthcare. Novo Nordisk and ASML detracted, while Legrand and Bankinter contributed positively. Over 12 months, the Trust’s NAV rose 1.8% and the share price 1.7%, compared with an 11.3% gain for the index.

European Investment Opportunities – Fidelity’s Quality Focus (LON:FEV)

FEV portfolio manager Marcel Stotzel highlights how quality companies with strong defensive characteristics can help investors navigate uncertainty and achieve long-term growth.

Search

Search